Will the WHO's Europe Regional Office finalize and publish its new digital health strategy by August 31, 2026?

This market resolves to Yes if the World Health Organization (WHO) publicly releases its global digital health strategy by July 31, 2026. Any official statement, publication, or press release confirming the release will constitute resolution. A lack of announcement or confirmation by this date resolves the market to No.

This market resolves to Yes if the U.S. Food and Drug Administration (FDA) announces formal approval of the first regenerative injection therapy for osteo-arthritis, as described in recent research news, by August 31, 2026. Any official FDA announcement, press release, or public database update confirming approval will determine the outcome. If no such approval is granted by the close date, the market resolves to No.

Will Linear Health Sciences' Orchid SRV be launched in Japan by July 22, 2026?

This market resolves to Yes if Linear Health Sciences and NIPRO CORPORATION launch the Orchid Safety Release Valve (SRV) in the Japanese market on or before July 22, 2026, as per their announcement. The launch must involve public confirmation of product availability in Japan or sales starting by the specified date, confirmed through media reports or an official press release.

This market resolves to Yes if it is confirmed that the National Health Service (NHS) has begun pilot studies implementing the non-invasive tests for endometriosis recommended by NICE (National Institute for Health and Care Excellence) by August 31, 2026. Public confirmation may come from NHS press releases, reputable UK health media outlets, or official NICE/NHS communications.

This market resolves to Yes if the UK’s National Institute for Health and Care Excellence (NICE) announces an official recommendation for at least one new non-invasive diagnostic test for endometriosis by August 31, 2026. The resolution will be based on verifiable public announcements or publications by NICE.

This market resolves to Yes if any new state-level regulations specific to Utah's AI-driven prescription refill pilot program are officially enacted by August 31, 2026. This includes legislation, healthcare board policies, or executive actions aimed explicitly at modifying, expanding, or restricting the program. Public announcements or documented evidence of such changes will determine resolution.